Review of depot aripiprazole for schizophrenia

Review of depot aripiprazole for schizophrenia

Farha Bilal Motiwala, Kim Stasia Siscoe, Rif S El-Mallakh Mood Disorders Research Program, Department of Psychiatry and Behavioral Sciences, University of Louisville School of Medicine, Louisville, KY, USA Abstract: Improving outcomes in schizophrenia generally requires an improvement in medication...

Full description

Bibliographic Details
Main Authors:	Motiwala FB, Siscoe KS, El-Mallakh RS
Format:	Article
Language:	English
Published:	Dove Medical Press 2013-11-01
Series:	Patient Preference and Adherence
Online Access:	http://www.dovepress.com/review-of-depot-aripiprazole-for-schizophrenia-a14976

Similar Items

Síndrome neuroléptico maligno por aripiprazol depot
by: A. Contreras Chicote, et al.
Published: (2023-06-01)

Aripiprazole in schizophrenia: consensus guidelines.
by: Travis, M, et al.
Published: (2005)

Clinical experience with the new double aripiprazole depot regime in a psychiatric hospitalization unit
by: Á. Moleón Ruiz, et al.
Published: (2022-06-01)

Xanomeline-Trospium and Muscarinic Involvement in Schizophrenia
by: Kidambi N, et al.
Published: (2023-05-01)

Differences in autonomic nervous system activity between long-acting injectable aripiprazole and oral aripiprazole in schizophrenia
by: Saki Hattori, et al.
Published: (2023-03-01)

The use of aripiprazole in early onset schizophrenia: safety and efficacy
by: Ibrahim, Normala, et al.
Published: (2009)

Treatment of refractory catatonic schizophrenia with low dose aripiprazole
by: Sasaki Tsuyoshi, et al.
Published: (2012-05-01)

The role of aripiprazole in improvement of penile erection in schizophrenia patients with erectile dysfunction
by: Debby Handayati Harahap, et al.
Published: (2021-08-01)

Participant Engagement and Symptom Improvement: Aripiprazole Tablets with Sensor for the Treatment of Schizophrenia
by: Cochran JM, et al.
Published: (2022-07-01)

Effects of Aripiprazole on Olanzapine Population Pharmacokinetics and Initial Dosage Optimization in Schizophrenia Patients
by: Zhang C, et al.
Published: (2024-03-01)

Aripiprazole lai two-injection start in a 16 year-old with Schizophrenia
by: B. Marpepa, et al.
Published: (2022-06-01)

Aripiprazole in the treatment of acute episode of schizophrenia: a real-world study in China
by: Qian Li, et al.
Published: (2023-05-01)

Aripiprazole treatment effects on metabolic syndrome parameters in schizophrenia patients: Preliminary results
by: Said, M.A., et al.
Published: (2010)

Combined Aripiprazole and Electroconvulsive Therapy in a Patient with Treatment-Resistant Schizophrenia and QT Prolongation
by: Nordin, Muhammad Farhan, et al.
Published: (2018)

Hypoprolactinemia and hyperprolactinemia in male schizophrenia patients treated with aripiprazole and risperidone and their relationships with testosterone levels
by: Minami Tasaki, et al.
Published: (2021-09-01)

Augmentation of aripiprazole by flupenthixol decanoate in poorly responsive schizophrenia: a randomized clinical study
by: Saeed Shoja Shafti
Published: (2017-07-01)

Aripiprazole LAI two‐injection start in a 16 year‐old adolescent with schizophrenia
by: Virginio Salvi, et al.
Published: (2022-06-01)

Dynamics of mental state and prolactin levels in patients with chronic schizophrenia during aripiprazole therapy
by: L. N. Gorobets, et al.
Published: (2023-07-01)

Aripiprazole Lauroxil, a Novel Injectable Long-Acting Antipsychotic Treatment for Adults with Schizophrenia: A Comprehensive Review
by: Kunal Maini, et al.
Published: (2021-07-01)

Chlorine Atoms of an Aripiprazole Molecule Control the Geometry and Motion of Aripiprazole and Deschloro-aripiprazole in Subdomain IIIA of Human Serum Albumin
by: Akito Kawai, et al.
Published: (2022-08-01)

Place of the partial dopamine receptor agonist aripiprazole in the management of schizophrenia in adults: a Delphi consensus study
by: Pierre-Michel Llorca, et al.
Published: (2022-05-01)

Taiwan Expert Consensus Recommendations for Switching to Aripiprazole Long-Acting Once-Monthly in Patients with Schizophrenia
by: Chih-Sung Liang, et al.
Published: (2021-11-01)

Effects of aripiprazole long-acting two-injection start in patients diagnosed with schizophrenia in Huelva (Spain)
by: A. Moleon, et al.
Published: (2023-03-01)

Improvement of functioning in patients with schizophrenia: real-world effectiveness of aripiprazole once-monthly (REACT study)
by: Oloruntoba Oluboka, et al.
Published: (2023-05-01)

Efficacy and tolerability of aripiprazole versus D2 antagonists in the early course of schizophrenia: a systematic review and meta-analysis
by: David D. Kim, et al.
Published: (2021-05-01)

Efficacy and tolerability Aripiprazole once-monthly long-acting injectable in schizophrenia. Two-injection start regimen
by: S.L. Romero Guillena, et al.
Published: (2022-06-01)

Determination of Changes in Blood Biomarker Levels in Antipsychotic Polypharmacy and Aripiprazole Monotherapy in Patients With Long-term Schizophrenia
by: Venus Vatankhah, et al.
Published: (2019-12-01)

Aripiprazole-induced transient myopia
by: Tongabay Cumurcu, et al.
Published: (2020-10-01)

DIURNAL ENURESIS SECONDARY TO ARIPIPRAZOLE
by: Huseyin BAYAZIT
Published: (2017-09-01)

Aripiprazole-induced rosacea. Case report and literature review
by: T. Gutiérrez Higueras, et al.
Published: (2021-04-01)

Aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia: a 12-month, randomized, naturalistic trial.
by: Cipriani, A, et al.
Published: (2013)

The use of concurrent long-acting injectable antipsychotic therapy with paliperidone palmitate and aripiprazole monohydrate in a patient with schizophrenia
by: Christopher Evernden, BSc, BScPharm, ACPR, et al.
Published: (2021-09-01)

Healthcare resource use and costs reduction with aripiprazole once-monthly in schizophrenia: AMBITION, a real-world study
by: Vanessa Sanchez-Gistau, et al.
Published: (2023-08-01)

Aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia in routine clinical care: a randomized, controlled trial.
by: Barbui, C, et al.
Published: (2011)

Rationale and design of an independent randomised controlled trial evaluating the effectiveness of aripiprazole or haloperidol in combination with clozapine for treatment-resistant schizophrenia.
by: Nosè, M, et al.
Published: (2009)

N-Acetylcysteine and Aripiprazole Improve Social Behavior and Cognition and Modulate Brain BDNF Levels in a Rat Model of Schizophrenia
by: Zofia Rogóż, et al.
Published: (2022-02-01)

Clinical insight among persons with schizophrenia spectrum disorders treated with amisulpride, aripiprazole or olanzapine: a semi-randomised trial
by: L.A Stabell, et al.
Published: (2023-06-01)

Hyperprolactinaemia and menstrual irregularity emerging in association with risperidone use and treated with aripiprazole in an adolescent diagnosed with schizophrenia: a case report
by: Şermin Bilgen Ulgar, et al.
Published: (2018-10-01)

Aripiprazole alone or in combination for acute mania.
by: Brown, R, et al.
Published: (2013)

Aripiprazole--data on efficacy and associated mortality.
by: Crow, T
Published: (2007)